What is Kytopen?
Kytopen operates at the intersection of biotechnology and advanced engineering, specializing in non-viral gene delivery systems. Its core innovation, the Flowfect platform, facilitates the rapid and consistent introduction of genetic materials—including DNA, mRNA, and CRISPR-based tools—into living cells. By replacing traditional, often inefficient viral vector methods with a scalable, continuous flow process, Kytopen addresses the primary bottlenecks in cell therapy production. This technological advantage is essential for biotech organizations aiming to streamline complex workflows and enhance the consistency of therapeutic manufacturing, ultimately reducing the time and cost associated with bringing life-saving treatments to market.
How much funding has Kytopen raised?
Kytopen has raised a total of $33.6M across 2 funding rounds:
Angel/Seed
$3.6M
Series A
$30M
Angel/Seed (2019): $3.6M with participation from The Engine and Horizons Ventures
Series A (2021): $30M led by Horizon Ventures, Northpond Ventures, and Mass Ventures
Key Investors in Kytopen
Horizons Ventures
Horizons Ventures focuses on investing in deep science and technology aimed at advancing humanity towards a significantly improved future.
Northpond Ventures
Northpond Ventures is a prominent investment firm specializing in science, technology, and healthcare, with a focus on long-term value creation.
Mass Ventures
MassVentures is dedicated to empowering entrepreneurs by providing essential resources to transform their ideas into reality.
What's next for Kytopen?
With this latest infusion of capital, Kytopen is positioned to scale its manufacturing capabilities and expand its commercial footprint within the global cell therapy sector. The strategic focus will likely shift toward optimizing the Flowfect platform for clinical-grade production, ensuring that the company remains at the forefront of biomanufacturing innovation. As the industry moves toward more personalized medicine, Kytopen's ability to provide consistent, high-throughput cell modification will be a key differentiator. Future milestones will likely involve deeper integration into the supply chains of major pharmaceutical partners and the continued refinement of its engineering solutions to meet the rigorous demands of regulatory-compliant, large-scale therapeutic development.
See full Kytopen company page
